Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
- assess the effectiveness of lenalidomide for the treatment of patients with relapsed and
or refractory peripheral T-cell lymphomas; and,
- assess the safety of lenalidomide.
There are reports suggesting a therapeutic benefit of thalidomide in patients with refractory
and/or relapsed Non-Hodgkin's Lymphoma's (NHL) which have led to the formal investigation of
lenalidomide in the treatment of relapsed NHL's.